Inventor · disambiguated record
Neil Bifulco, Jr.
Also filed as: BIFULCO JR NEIL · BIFULCO NEIL
19 granted patents·11 pending applications·374 citations·filing 2002–2023
95Inventor score
Files withBLUEPRINT MEDICINES CORP15ADJABENG GEORGE3BIFULCO JR NEIL3RECLUDIX PHARMA INC3ENTASIS THERAPEUTICS LTD2
Top patents by PatentIndex Score
30 records- 0198US9695165B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jul 4, 2017·40 cites·20 claims
- 0297US10000490B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jun 19, 2018·30 cites·12 claims
- 0397US9340514B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted May 17, 2016·43 cites·11 claims
- 0497US8802697B2Inhibitors of the fibroblast growth factor receptorBIFULCO JR NEIL·Filed 2013·Granted Aug 12, 2014·91 cites·9 claims
- 0596US9434700B2Inhibitors of the fibroblast growth factor receptorBIFULCO JR NEIL·Filed 2014·Granted Sep 6, 2016·45 cites·4 claims
- 0696US9126951B2Inhibitors of the fibroblast growth factor receptorBIFULCO JR NEIL·Filed 2014·Granted Sep 8, 2015·47 cites·41 claims
- 0795US10017512B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 10, 2018·29 cites·26 claims
- 0893US10221154B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2016·Granted Mar 5, 2019·11 cites·10 claims
- 0991US11970498B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 30, 2024·1 cites·26 claims
- 1090US11046697B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2018·Granted Jun 29, 2021·5 cites·20 claims
- 1189US11932648B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 19, 2024·1 cites·18 claims
- 1283US10875837B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2019·Granted Dec 29, 2020·1 cites·6 claims
- 1378US7807673B22-pyrimidinyl pyrazolopyridine ErbB kinase inhibitorsGLAXOSMITHKLINE LLC·Filed 2006·Granted Oct 5, 2010·7 cites·25 claims
- 1476US9309245B2Beta-lactamase inhibitor compoundsENTASIS THERAPEUTICS LTD·Filed 2013·Granted Apr 12, 2016·4 cites·20 claims
- 1576US7645771B2CCR5 antagonists as therapeutic agentsSMITHKLINE BEECHAM CORP·Filed 2003·Granted Jan 12, 2010·16 cites·4 claims
- 1673US10370379B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2016·Granted Aug 6, 2019·1 cites·12 claims
- 1773US9623014B2β-lactamase inhibitor compoundsENTASIS THERAPEUTICS LTD·Filed 2016·Granted Apr 18, 2017·2 cites·22 claims
- 1871US2021347756A1Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2020·Application pending·0 cites
- 1966US2019359682A1Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2018·Application pending·0 cites
- 2061US2025215030A1Stat modulators and uses thereofRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 2160US2025215029A1Stat modulators and uses thereofRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 2258US2017066812A1Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2016·Application pending·0 cites
- 2358US2025179103A16-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4h-pyrrolo[2,1-d][1,5]thiazocine derivatives as stat3 and stat6 modulators for the treatment of cancer and inflammatory conditionsRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 2458US2024287040A1Substituted pyrimidinyl-pyrazoles as cdk2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 2555US11059827B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2019·Granted Jul 13, 2021·0 cites·19 claims
- 2648US2011098296A1Thiazole And Oxazole Kinase InhibitorsADJABENG GEORGE·Filed 2008·Application pending·0 cites
- 2744US2011190280A1Thiazole And Oxazole Kinase InhibitorsADJABENG GEORGE·Filed 2008·Application pending·0 cites
- 2838US2004180891A1Pyrazole derivatives useful in the treatment of hyper-proliferative disordersFiled 2002·Application pending·0 cites
- 2930US2011319392A1Thiazole Sulfonamide And Oxazole Sulfonamide Kinase InhibitorsADJABENG GEORGE·Filed 2010·Application pending·0 cites
- 3021US8569484B2Heterocyclic urea derivatives and methods of use thereofBIFULCO NEIL·Filed 2010·Granted Oct 29, 2013·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Neil Bifulco, Jr. files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →